The Vaping Regulatory Survivor: What the PMTA Process Is Doing to Product Innovation

The independent vaping industry—the hundreds of small and medium-sized companies that developed the products, built the supply chains, and created the consumer market for e-cigarettes—is dying. Not because consumers stopped buying their products, or because their products were unsafe, or because they were outcompeted on quality or price. It is dying because the regulatory process that was supposed to bring order and safety to the market has, in practice, made the market inaccessible to any company that lacks the resources of a multinational tobacco corporation. The PMTA process, with its million-dollar-per-product cost, its complex evidentiary requirements, and its uncertain timeline, has functioned as a market-exclusion mechanism—a filter that lets through the largest companies and blocks everyone else. The 23 products that FDA has authorized represent a tiny fraction of the market that existed before the PMTA deadline. The thousands of products that were denied or that remain in regulatory limbo represent the diversity, the innovation, and the consumer choice that characterized the vaping market before the regulatory crackdown. What has been lost is not just products. It is the innovation ecosystem that made vaping an effective smoking-cessation tool.

The innovation that the independent vaping industry produced was not incremental. It was transformative. The transition from cigalikes (first-generation devices that looked like cigarettes and delivered nicotine poorly) to vape pens (second-generation devices with refillable tanks and better battery life) to mods (third-generation devices with variable power, temperature control, and user-rebuildable components) was driven by small companies responding to consumer feedback, iterating rapidly, and competing on performance. The development of nicotine salts—the chemistry breakthrough that made high-nicotine vaping tolerable and that enabled the pod-system revolution—was the work of Juul, a startup founded by Stanford design students, not a major tobacco company. The flavor innovation that made vaping appealing to adult smokers—the thousands of e-liquid flavors that gave smokers distance from the cigarette taste and that made vaping a satisfying alternative—was produced by small e-liquid manufacturers operating with minimal regulatory oversight. The independent vaping industry was messy, unregulated, and occasionally reckless—but it was also extraordinarily innovative, and the products it produced are the products that millions of smokers used to quit cigarettes.

The PMTA process, as currently structured, cannot replicate the innovation ecosystem that it has largely eliminated. The process requires manufacturers to demonstrate that their products are 'appropriate for the protection of public health'—a standard that involves demonstrating that the product will not increase youth initiation, will promote smoking cessation among adults, and will have a net positive population-level health impact. For an established product from a major company—a Vuse pod system, a Logic vape pen—the evidentiary burden is substantial but manageable: the company can fund the required studies, compile the existing evidence, and navigate the regulatory process with the expertise of its in-house regulatory affairs team. For a small company with a novel product—a new device design, a new nicotine formulation, a new approach to harm reduction—the evidentiary burden is insurmountable. The company cannot fund the studies, does not have the regulatory expertise, and cannot sustain the years of regulatory uncertainty while the application is pending. The PMTA process selects for incumbency—the companies that can afford to comply are the companies that are already in the market, and the companies that are already in the market are the companies whose products were developed before the PMTA process was implemented. The process selects against innovation—the companies with new ideas cannot afford to test them, and the regulatory pathway for novel products is effectively closed.

The consequences for consumer choice are already visible. The vaping products that are available through legal channels are increasingly homogeneous—a small number of pod systems and disposables from the major companies, with limited flavor options (tobacco, menthol, and a small number of fruit or dessert flavors in jurisdictions where flavors are not banned) and standardized nicotine concentrations. The diversity of products that characterized the pre-PMTA market—the mechanical mods, the rebuildable atomizers, the custom e-liquids, the DIY mixing community—has been driven to the margins. The consumer who was using a specific flavor from a specific manufacturer, at a specific nicotine concentration, to stay off cigarettes may find that their product is no longer available—and that the alternatives satisfy less effectively. The public health consequence is that some proportion of these consumers will return to smoking—a consequence that the PMTA process acknowledges as a possibility but that it has no mechanism for measuring or mitigating. The regulatory clearance that was supposed to make vaping safer may, by reducing the effectiveness of the products that reach the market, make the public health outcome worse.

The loss of the independent vaping industry has implications for the future of nicotine innovation. The next breakthrough—the product that competes with cigarettes on satisfaction more effectively than current vaping products, that addresses the limitations of current nicotine pouches, that solves the environmental problems of disposables—is likely to come from outside the major tobacco companies, as the previous breakthroughs did. The PMTA process, by making the regulatory pathway prohibitively expensive for independent innovators, has effectively closed the door to the next breakthrough. The major tobacco companies have the resources to innovate but not the incentive—their cigarette businesses are still enormously profitable, and genuinely disruptive innovation in reduced-risk products would cannibalize their cigarette revenue. The independent innovators that have the incentive to disrupt cannot afford to navigate the regulatory pathway. The result is a market that is structured to preserve the status quo—cigarettes remain dominant, reduced-risk products are incremental rather than disruptive, and the innovation that could accelerate the transition away from combustion is systematically suppressed.

Reforming the PMTA process to preserve innovation while maintaining safety standards is possible but politically difficult. A tiered regulatory pathway—with a streamlined, lower-cost option for products that are substantially equivalent to already-authorized devices, and a full-review pathway for genuinely novel products—would reduce the barrier to entry for incremental innovation while maintaining scrutiny of novel products. An 'innovation exemption' that allows small companies to market products without full PMTA authorization, subject to post-market surveillance and safety reporting, would preserve the innovation ecosystem while maintaining regulatory oversight. Both proposals face opposition: from the public health advocacy community, which views any relaxation of the PMTA requirements as a concession to the industry; and from the major tobacco companies, which benefit from a regulatory structure that eliminates their independent competitors. The status quo, as dysfunctional as it is from a public health and innovation perspective, has powerful beneficiaries.

Shareable insight: The independent vaping industry—the hundreds of small companies that created the e-cigarette market and drove the innovation that made vaping an effective smoking-cessation tool—has been effectively eliminated by the PMTA process. The 23 products authorized by FDA are all from major tobacco companies. The diversity, the innovation, and the consumer choice that characterized the pre-PMTA market have been replaced by a regulatory oligopoly. The products that millions of smokers used to quit cigarettes may no longer be available—and the innovation that could produce the next breakthrough has been priced out of the regulatory pathway.